Network pharmacology combined with experimental validation reveals the mechanism of action of erpixing granules on functional dyspepsia

作者：Yuanmei Bai, Feifan Liu, Yan Wan, Xue Wu, Shifang Luo, Linao Zhang, Hua Tang, Tao Li, Xianjin Tang, Wen Long Qin, W. Gan, Ying Yang, Zili Yin, Yuhuan Xie, Peixin Guo · 发表于：Journal of Ethnopharmacology · 年份：2024 · DOI：10.1016/j.jep.2024.118553 · 被引用次数：11 · 研究领域：Gastrointestinal motility and disorders、Helicobacter pylori-related gastroenterology studies、Barrier Structure and Function Studies

ETHNOPHARMACOLOGICAL RELEVANCE: Functional dyspepsia (FD) is a prevalent gastrointestinal disorder characterised by high incidence and recurrence rates, posing significant health risks. Erpixing Granules (EPX), approved by the National Food and Drug Administration in 2002, are known for their spleen and stomach invigorating properties, effectively treating FD. However, its mechanism of action remains unclear. AIM OF THE STUDY: This study aims to elucidate EPX's mechanism of treating FD through network pharmacology, and experimental validation using FD animal models. METHODS: In this study, the chemical composition of EPX in positive and negative ion modes was analyzed by UHPLC-Q-TOF MS. The mass spectral data were processed and analyzed using MS-DIAL software to automatically match compound fragment information and identify the known components with the compound database to obtain the active components of EPX. SwissTargetPrediction was used to obtain EPX targets, while FD-related targets were sourced from GeneCards, OMIM and DisGeNET databases. A protein-protein interaction (PPI) network was constructed using the STRING platform, and potential signalling pathways of EPX were determined through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. Finally, an FD model was established in rates by administering a 0.1% iodoacetamide sucrose solution, followed by tail clamp stimulation to experimentally validate the network pharmacology finding...